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ABSTRACT 
Adipose-derived secreted factors termed adipokines affect both metabolic 
and cardiovascular function. Previous studies have shown that ablation of the 
adipokine adiponectin leads to endothelial and metabolic dysfunction, whereas 
its overexpression is protective. However, the receptor(s) mediating the 
protective effects of adiponectin on the vasculature are not known. The goal of 
this study was to elucidate the role of three adiponectin receptors: T -cadherin, 
AdipoR1, and AdipoR2, in the revascularization response to chronic ischemia 
and the metabolic adaptation to diet-induced obesity. 
T -cadherin is a membrane protein which localizes adiponectin to the 
vascular endothelium. In a model of peripheral artery disease, T -cadherin-
deficient mice phenocopy adiponectin-deficient mice such that both strains 
display impaired blood flow recovery compared to wild-type controls. Adiponectin 
delivery rescued the impaired revascularization phenotype in adiponectin-
deficient mice, but not in T-cadherin-deficient mice. In cultured endothelial cells, 
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T -cadherin deficiency prevented the ability of adiponectin to promote cellular 
migration and proliferation. These data highlight a previously unrecognized role 
forT -cadherin in limb revascularization, and show that it is essential for 
mediating the vascular actions of adiponectin. 
AdipoR1- and AdipoR2-deficient mice were also subjected to hind limb 
ischemia surgery to determine their role in vascular function. Blood flow recovery 
in AdipoR1-deficient mice was similar to wild-type; however, revascularization in 
AdipoR2-deficient mice was severely attenuated. Adiponectin administration 
enhanced the recovery of wild-type but not AdipoR2-deficient mice. These data 
show for the first time that AdipoR2 is functionally important in an in vivo model of 
vascular disease and that its expression is essential for the revascularization 
actions of adiponectin. 
Since adiponectin also plays an important role in metabolic disease, T-
cadherin-, AdipoR1- and AdipoR2-deficient mice were evaluated in a model of 
diet-induced obesity. No differences in metabolic function were detected at 
baseline between wild-type and any of these knockout strains. On a high-calorie 
diet, T -cadherin-deficient mice developed glucose intolerance despite an 
attenuated weight gain. Strikingly, AdipoR1-deficiency resulted in severe 
metabolic dysfunction and increased body weight, whereas, AdipoR2-deficiency 
was protective against diet-induced weight gain and metabolic perturbations. 
These studies show that T-cadherin, AdipoR1 and AdipoR2 have important yet 
divergent roles in mouse models of vascular and metabolic disease. 
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CHAPTER I 
INTRODUCTION 
Adipokine concept 
In the United States, the incidence of obesity continues to increase at a 
steady rate. It is well-appreciated that elevated body mass index (BMI) is 
associated with an increased risk of cardiovascular disease and overall mortality. 
A recent study concluded that severe obesity (BM I >40 kg/m2) can shorten 
lifespan by up to 10 years and vascular disease is the main cause of mortality in 
obese individuals 1. The mechanisms underlying obesity-associated mortality are 
incompletely understood. Adipose tissue (fat) is composed of a variety of cell 
types including adipocytes, fibroblasts, T cells, macrophages, vascular smooth 
muscle cells and endothelial cells (Figure 1-1 ). Adipose from individuals of 
normal weight has adequate blood vessel infiltration, small adipocytes, CD4+ T 
cells and alternatively activated M2 macrophages. The adipose depot expands 
with obesity as adipocytes increase in size to accommodate excess triglycerides. 
Classically activated M1 macrophages and CD8+ T cells accumulate in the tissue 
creating a pro-inflammatory environment2. Hallmark features of adipose tissue 
from obese, metabolically dysfunctional subjects are crown-like structures of 
macrophages surrounding necrotic adipocytes (Figure 1-1 ). 
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Excess fat accumulation can extend beyond the primary energy storage 
sites, subcutaneous and visceral adipose tissue, and lead to ectopic fat 
accumulation in the liver, heart and muscle. Besides energy storage, adipose 
tissue has an important endocrine function. Factors secreted from this tissue are 
termed adipokines (Table 1-1 ), and many are pro-inflammatory while a subset 
has anti-inflammatory functions2 . With increasing adiposity, expression of pro-
inflammatory adipokines is increased while expression of anti-inflammatory 
adipokines is reduced. This change in adipokine profile significantly contributes 
to the systemic state of low-grade inflammation observed in obese individuals. 
Adipocyte 
Lean with normel 
metaboUc function 
... Inflammation 
... Metabolic control 
... Vascular function 
Obese with mild 
metaboUc dysfunction 
/ Ml moorophogo 
.-----------------. AntH nftarnmetory edlpoklnes 
Adiponectin 
SFRP5 
Obese with full 
metabolic dysfunction 
structure 
Pro-tnftemmetory edipoldnes 
leptin ANGPTL2 CCL2 
Resistin TNF CXCL5 
RBP4 ll·6 NAMPT 
lipocolin 2 ll-18 
FIGURE 1-1. Inflammatory, metabolic and vascular consequences of obesity. The 
adipose tissue of obese individuals is marked by adipocyte hypertrophy, infiltration of 
inflammatory cells, and impaired vascularity. In lean, healthy subjects, the expression of anti-
inflammatory factors predominates while the adipose tissue of obese subjects secretes more 
pro-inflammatory factors. Through modulation of serum adipokine levels, the adipose tissue 
microenvironment can have systemic effects on inflammatory state, metabolic control and 
vascular function. Diagram from Ouch i, Parker, Lug us, and Walsh 2. 
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Table 1-1. Source, receptor and function of selected adipokines. 
Adipokines may be derived from different cellular sources within adipose 
tissue, including macrophages and adipocytes. Although some are 
unknown, the binding proteins for adipokines include both plasma 
membrane-localized receptors and soluble factors. Adipokines have 
diverse actions influencing inflammation and metabolism. Table from Ouchi, 
Parker, Lugus, and Walsh2 . 
Adipokine 
leptin 
Re~istin 
RBP4 
lipocalin2 
ANGPTU 
lNF 
IL-6 
IL-18 
CCL2 
CXCL5 
NAMPT 
Adiponectin 
SFRP5 
Primary source(s) 
Adipocytes 
Peripheral btood mononuclear 
cells (h~man).adipocytes 
(rodent) 
Liver. adipocytes. macrophages 
Adipocytes. macrophages 
Adipocytes.. other cells 
Stromal vascular fraction cells. 
ad\pocytes 
Adipocytes. stromal vascular 
fraction cells. liver. muscle 
Stromal vascular fraction cells 
Adipocytes.. stromal vascular 
fract ion cells 
Stromal vascular fraction cells 
(macrophages) 
Adipocytes. macrophages. 
other cells 
Adipocytes 
Adipocytes 
Binding partner or receptor 
Leptin receptor 
Unknown 
Retinol(vitamin A). 
transthyretin 
Unknown 
Function 
Appetite control through the 
central nervous system 
Promotes insulln resistance and 
inflammation through IL -6 and 
TNF secretion from macrophages 
Implicated in systemic insulin 
resistance 
Promotes insulln resistance 
and inflammation through TN F 
secretion from adipocytes 
Unknown Local and vascular inflammation 
TNF receptor Inflammation. antagonism of 
insulln signalling 
IL -6 receptor Changes with source and target 
tissue 
IL-18 receptor. ll -18 binding Broad-spectrum inflammation 
protein 
CCR2 Monocyte recruitment 
CXCR2 Antagonism ofinsulln signalling 
through the JAK-STAT pathway 
Unknown Monocyte chemotactic activity 
Adiponectin receptors li and 2, Insulin sensitizer. 
T-cadherln. calreticulin-CD01 anti-inflammatory 
WNT5a Suppression of pro-inflammatory 
WNT signalling 
ANGPTL2, angi.opoietin·like protein 2; CCL2, CC-chamokina li gand 2; CXCLS. CXC-chem.okina ligand 5; IL. interleukin;JAK. Janus 
kinase; NAMPT, nicotinamide phosphoribos'jil.transferna; RBP4,retinol-binding p rotein 4; SFRPS, secreted fri:u.ted-relat ad protein 5; 
STAT, signal transducer and activator of transcription; T F, tumour necros·i• factor. 
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Identification and characterization of adiponectin 
Adiponectin was simultaneously identified by 4 groups in 1995-19963-6. It 
was originally termed adipocyte complement related protein of 30kDa (Acrp30) 
because of its structural similarity to complement 1q (C1q)3 . Like C1q, 
adiponectin has a collectin-like structure with a globular head and a collagenous 
tail and monomeric subunits coalesce to form large oligomeric structures. 
Adiponectin circulates as three distinct fractions including trimers, hexamers and 
high molecular weight isoforms that are composed of 12 to 18 monomers. The 
high molecular weight isoform is considered to be the most biologically active7 . 
The adiponectin isoforms are assembled inside the adipocyte and once secreted, 
they do not interconvert8 . The trimeric form undergoes proteolytic cleavage, at 
least in vitro, to form an 18-25kDa globular fragment9. Similar cleavage may also 
occur in vivo by leukocyte elastase secreted by tissue-resident inflammatory 
cells 10 but arguing against this is the fact that circulating levels of globular 
adiponectin are barely, if at all, detectable 11 ·12. 
Maeda, et al. termed the newly discovered adiponectin protein, adipose 
most abundant gene transcript 1 (apM1) due to its high expression in fat5. 
Serum levels of adiponectin in normal, healthy indfviduals can exceed 401-Jg/ml. 
The primary clearance site is the liver and half-life of adiponectin is 75 and 45 
minutes for the high molecular weight and low molecular weight isoforms, 
respectiveli 3. In general, males have less total and high molecular weight 
adiponectin than females8 . In obese individuals, serum adiponectin levels are 
4 
significantly reduced6·14. Weight loss is one clinical intervention that elevates 
serum adiponectin to normal levels 15. The strong negative association between 
adiponectin levels and body mass index reflects a decreased production since 
the protein half-life doubles in mouse models of obesity13. 
Adiponectin and immunometabolism 
Adiponectin has diverse effects throughout the body including 
cardiovascular protection and metabolic regulation. Many of these protective 
actions can be attributed to its anti-inflammatory properties. Ouchi, et al. 
reported that adiponectin inhibits nuclear factor KB (NF-KB) activation in 
endothelial cells following treatment with pro-inflammatory factors such as tumor 
necrosis factor a (TNFa)16. Conversely, TNFa inhibits expression of adiponectin. 
We and others recently extended the observation that adiponectin has anti-
inflammatory effects by specifically identifying that this adipokine promotes M2 
macrophage polarization 17-19. M1 macrophages are polarized by 
lipopolysaccharide and express inducible nitric oxide synthase (iNOS), whereas 
M2 macrophages are polarized by IL-4 and express arginase-1 20. M2 
macrophages are thought to be important in debris clearance, wound healing and 
tissue repair. Adiponectin has been shown to promote macrophage clearance of 
apoptotic cells via interaction with cell surface proteins calreticulin (CRT) and low 
density lipoprotein related receptor (LRP1 )21 . The ability of adiponectin to reduce 
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inflammation and promote M2 polarization contributes to the observed protective 
effects of adiponectin in the metabolic and cardiovascular systems. 
Intriguingly, adiponectin binds a number of serum proteins including 
LPS22, Factor H23, and C 1 q24•25, chemokines26 and growth factors27•28 . C 1 q-
adiponectin complexes can be measured in human serum by a novel ELISA 
system25. The hexamer and high molecular weight isoforms of adiponectin bind 
C1q. The ratio of C1q-adiponectin to total adiponectin is increased in diabetic 
patients with coronary artery disease29. Treatment with the thiazolidinedione 
(TZD), pioglitazone, reduced the fraction of serum adiponectin bound to C1q30. 
An earlier report found that upon binding C1q, adiponectin activated the 
complement casade24• However, consistent with its known anti-inflammatory 
actions, binding to C1q may serve to sequester inflammatory factors and inhibit 
signaling27. It is not known how formation of adiponectin-serum protein 
complexes in vivo affects the activity of each protein. 
Numerous studies to date have examined the insulin-sensitizing actions of 
adiponectin. Mouse genetic evidence suggests that overexpression of globular 
or full-length adiponectin is protective in mouse models of obesity, such as the 
oblob leptin-deficient mouse31 ·32• Despite having an elevated body weight 
compared to ob/ob mice, the excess serum adiponectin in ob/ob adiponectin 
transgenic mice promoted metabolic function31 . This may be due to expansion of 
the number of adipocytes in adipose tissue, whereas weight gain is usually 
marked by adipocyte hypertrophl3. Yamauchi et al. demonstrated that 
6 
adiponectin modulates glucose uptake, gluconeogenesis and fatty acid oxidation 
in skeletal muscle and liver through AMPK and PPARa signaling pathways33• 
Adiponectin may also be atheroprotective. For example, apoE-deficient 
mice were protected from development of atherosclerosis by overexpression of 
globular32 or full-length adiponectin34• During the development of 
atherosclerosis, circulating monocytes bind endothelial adhesion molecules, 
migrate into the intima and differentiate into macrophages. As plaque formation 
progresses, the macrophages take up lipid and develop into foam cells35 . 
Matsuzawa and colleagues discovered that adiponectin reduces expression of 
vascular adhesion molecules, attenuates lipid accumulation and reduces 
scavenger A receptor expression in monocyte-derived macrophages 16·36. 
However, the role of adiponectin in mouse models of atherosclerosis remains 
controversial. For example, a very thorough in vivo study using adiponectin-
deficient, wild-type and adiponectin-transgenic mice bred onto two different 
atherogenic backgrounds found that adiponectin levels did not correlate with 
atherosclerosis severity37. Additional studies are needed to clarify the role of 
adiponectin in atherosclerosis. 
TZDs such as rosiglitazone and pioglitazone function as peroxisome 
proliferator activated receptor y (PPARy) agonists and are effective modulators of 
blood glucose in the diabetic population. TZDs elevate circulating adiponectin 
levels38 and tissue expression of adiponectin receptors 1 and 2 (AdipoR 1 and 
AdipoR2)39.4°. Adiponectin regulation occurs at a transcriptional level since the 
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adiponectin promoter has a PPAR-response element (PPAR-RE)41 . Angiotensin 
converting enzyme (ACE) inhibitors42 and angiotensin type 1 receptor blockers 
(ARBs)43 also increase circulating adiponectin levels through a PPAR-based 
mechanism. Rosiglitazone is ineffective in normalizing blood glucose levels in 
adiponectin-deficient mice. Similarly, by an adiponectin-dependent mechanism 
TZDs reduced pathological retinal neovascularization and improved vascular 
function in a model of diabetes. The beneficial metabolic and vascular actions of 
TZDs are, at least in part, dependent on expression of adiponectin4446. 
Cardiovascular and metabolic functions are strongly interconnected. 
Increased adipose tissue vascularity is associated with improved metabolic 
function and reduced accumulation of pro-inflammatory M1 macrophages. 
Serum adiponectin levels are positively associated with capillary density in 
adipose tissue (Aprahamian T, unpublished observations). Mice overexpressing 
pro-angiogenic vascular endothelial growth factor (VEGF) in adipose tissue had 
preserved metabolic function in a model of diet-induced obesity. Pro-angiogenic 
and anti-inflammmatory actions of adiponectin are presumed to allow for 
metabolic adaptation during the development of obesity including adipocyte 
proliferation31 and vascular cell migration and proliferation47 in order to maintain 
adequate nutrient supply to the tissue. 
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Role of adiponectin in peripheral artery disease 
Peripheral artery disease is a condition of reduced blood flow or occlusion 
of the non-cerebral, non-coronary arteries48. The cause of the vessel narrowing 
is typically atherosclerotic plaque accumulation. A patient with peripheral artery 
disease is at a higher risk of developing other cardiovascular complications 
including coronary artery disease and abdominal aortic aneurisms49. Advanced 
age, diabetes, smoking status, hyperlipidemia and hypertension are all risk 
factors for developing peripheral artery disease highlighting an important 
connection between metabolic and cardiovascular disease. Although patients 
with peripheral artery disease have reduced mobility, supervised exercise 
training is the most effective non-surgical intervention50. A common 
measurement used to assess disease severity is the ankle brachial pressure 
index (ABPI), which is a ratio of ankle to arm blood pressure48• In healthy 
individuals, the ratio is 0.9- 1.2, while the ratio in peripheral artery disease 
patients is 0.9- 0.5. Approximately 1-3% of peripheral artery disease patients 
progress to a classification of critical limb ischemia (ratio< 0.5). Surgical bypass 
or angioplasty is the first step taken to restore blood flow in these patients. 
However, the outcome for critical limb ischemia is poor with a 30% amputation 
rate and 25% mortality rate within one year of diagnosis 51• 
Previous studies have shown that adiponectin promotes revascularization 
following hind limb ischemia surgery. Mice deficient in adiponectin have impaired 
blood flow recovery compared with wild-type mice52. Administration of 
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adenovirus-expressing adiponectin promotes the revascularization response and 
rescues the impairment observed in adiponectin-deficient mice. Two intracellular 
signaling molecules that are important for this effect include 5' adenosine 
monophosphate-activated protein kinase (AMPK)52 and cyclooxygenase-2 (COX-
2)53. Treatment with an adenovirus-expressing dominant-negative AMPK 
(dnAMPK) attenuated blood flow recovery in wild-type mice. In addition, 
exogenous adiponectin treatment was ineffective at improving blood flow in the 
dnAMPK-treated mice. A similar study subjected endothelial cell-specific COX-2-
deficient mice to hind limb ischemia. Again, these mice had impaired 
revascularization that was not improved by adiponectin treatment. siRNA 
knockdown experiments suggested an in vitro role for AdipoR1 in the AMPK 
pathway and CRT/LRP1 in the COX-2 pathwal3. 
Extending these observations to the human population, a prospective 
study found that levels of total and high molecular weight adiponectin were 
inversely associated with development of peripheral artery disease54• In addition, 
low levels of adiponectin are associated with peripheral artery disease risk 
factors including smoking55, diabetes56, hyperlipidemia57 and hypertension58. 
Elevating circulating levels of adiponectin through diet, exercise or 
pharmacological intervention may be protective against development of 
metabolic and vascular disease. Additional therapeutic strategies include 
targeting the adiponectin receptor with a small molecule agonist or increasing 
tissue expression of the receptor. However, the receptor-mediated signaling 
10 
T-CADHERIN 
ADIPORl 
FIGURE 1-2. Adiponectin receptors. AdipoR1 and AdipoR2 are seven transmembrane 
receptors with the opposite topology as G-protein coupled receptors. T-cadherin is GPI-
Iinkedwith 5 extracellulardomains. 
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pathways conferring the vascular actions of adiponectin have not been identified. 
Candidate receptors include T-cadherin, AdipoR1 and AdipoR2 (Figure 1-2). 
Individual knockout mice for adiponectin binding proteins exist, but they have 
never been tested in a model of hind limb ischemia. The goal of this study is to 
develop mouse genetic evidence for a functional adiponectin-receptor interaction 
using both vascular and metabolic models. 
T-cadherin 
T -cadherin was first identified over two decades ago as an axon guidance 
molecule59 and modulator of neural crest cell migration60• It is now appreciated 
that T -cadherin has functions that extend beyond the typical cadherin behavior of 
cell-to-cell adhesion. T-cadherin is highly expressed in the vasculature including 
endothelial cells61 , smooth muscle cells62 and pericytes63 . It has been implicated 
in modulation of angiogenic activities in cultured endothelial cells; however, some 
studies report that it promotes angiogenesis64-s8, whereas others report its 
attenuation69•70• Importantly, T-cadherin has been shown to localize the 
hexameric and high molecular weight isoforms of adiponectin to tumor 
vasculature and heart tissue68•71 • In human subjects, single nucleotide 
polymorphisms in CDH13, the gene encoding T-cadherin, are associated with 
circulating levels of adiponectin72-77• Genome wide association studies have also 
identified links between CDH13 and cancer78, blood pressure79 , blood lipid 
levels80, metabolic syndrome81 •82, type II diabetes and ischemic stroke81 • Given 
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its high level of expression on vascular cells and its role in modulating angiogenic 
behavior, we hypothesized that the T -cadherin-adiponectin interaction would be 
important for the revascularization activity of this adipokine in ischemic tissue. 
AdipoR1 and AdipoR2 
Adiponectin receptors, AdipoR1 and AdipoR2, were initially identified by 
expression cloning83. The receptors are predicted to have seven transmembrane 
domains with the opposite topology of G protein-coupled receptors. Both 
AdipoR1 and AdipoR2 are ubiquitously expressed with the highest expression in 
skeletal muscle and liver, respectively. Yamauchi, et al. reported that in a mouse 
model of diet-induced obesity, deficiency of AdipoR1, AdipoR2 or both 
adiponectin receptors resulted in glucose intolerance33. Similarly, it has been 
reported that both whole body84 and muscle-specific85 AdipoR1-KO mice display 
metabolic dysfunction. Consistent with these observations, AdipoR1 
overexpression in rat skeletal muscle is reported to ameliorate insulin resistance 
and promote glucose uptake86. However, controversy about the metabolic 
functions of AdipoR1 and AdipoR2 also exists. Bjursell et al. independently 
constructed AdipoR1 and AdipoR2 gene knockout mice and reported that they 
display opposing effects on glucose metabolism84• AdipoR1-KO mice showed 
increased adiposity and decreased glucose clearance, whereas AdipoR2-KO 
mice were lean and displayed improved glucose clearance. Furthermore, a third 
strain of AdipoR2-KO mouse was constructed by Liu et al.87 Feeding a high-fat 
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diet had biphasic effects on this strain. Initially, AdipoR2-KO mice were resistant 
to metabolic dysfunction, but glucose homeostasis deteriorated as the high-fat 
feeding was continued. 
The aim of this study was to determine if expression ofT -cadherin, 
AdipoR1 and AdipoR2 is required for the revascularization activity of adiponectin 
in a mouse model of peripheral artery disease88. The first objective was to 
determine if "receptor"-deficiency in mice phenocopies the impairment in 
revascularization that is observed in adiponectin-deficient mice. Next, we 
assessed whether T-cadherin, AdipoR1 or AdipoR2 are essential for the pro-
vascularization effects of adiponectin by comparing the responses of wild type, 
adiponectin-deficient mice and "receptor"-deficient mice to the administration of 
exogenous adiponectin. Then, we examined whether cultured, receptor-deficient 
endothelial cells are defective in their pro-angiogenic responses to exogenously 
administered adiponectin. Finally, using the same mouse strains employed for 
the cardiovascular measurements, we analyzed the respective roles of T-
cadherin, AdipoR1 and AdipoR2 in metabolic dysfunction. 
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Hypothesis: 
One or more of the adiponectin binding proteins found to be important for 
metabolic function {T-cadherin, AdipoR1 , and AdipoR2) are also critical for the 
vascular actions of adiponectin. 
Specific aims: 
1 . Determine if expression of the candidate adiponectin receptors is required 
for localization of adiponectin to skeletal muscle tissue. 
2. Determine if expression of T-cadherin, AdipoR1 or AdipoR2 is important 
for mouse limb revascularization and the pro-angiogenic actions of 
adiponectin. 
3. Characterize the metabolic roles of AdipoR1 and AdipoR2 using a mouse 
model of diet-induced obesity. 
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CHAPTER II 
METHODS 
Mouse models 
Adiponectin-deficient (APN-KO) mice were provided by N. Maeda, T. 
Funahashi, andY. Matsuzawa (Osaka University, Osaka, Japan). T-cadherin-
deficient (Tcad-KO) mice( Charlton, 2010 #47) were provided by B. Ranscht 
(Burnham Institute, La Jolla, CA). T-cadherin-deficient, adiponectin-deficient 
double KO (TA-dKO) mice were produced for this study through in house cross-
breeding. Wild-type C57BU6 controls for APN-KO, Tcad-KO and TA-dKO mice 
were purchased from Charles River Laboratories. AdipoR 1-KO and AdipoR2-KO 
mice were originally created by Deltagen and ordered from Mutant Mouse 
Regional Resource Centers (MMRRC) and Jackson Labs (#005775), 
respectively. AdipoR1-KO and AdipoR2-KO mice were maintained as 
heterozygous breeding pairs and wild-type littermates were used as controls. All 
mice were in a C57BL/6 background. The IACUC of Boston University approved 
all study procedures. Mice were maintained in a 12 hour light/dark schedule and 
given chow diet and water ad libitum, unless specified otherwise. 
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Immunofluorescence 
Gastrocnemius muscles from WT, APN-KO, Tcad-KO, AdipoR1 KO and 
AdipoR2 KO mice were embedded in OCT compound. Cryostat sections of 51-Jm 
were cut. Specimens were fixed by 4% paraformaldehyde for 15 minutes. Non-
specific binding sites were blocked with 3% horse serum and 3% bovine serum 
albumin in PBS for 1 hour at room temperature. Then, samples were incubated 
with both goat polyclonal anti-T-cadherin antibody (R&D Systems) and rabbit 
polyclonal anti-adiponectin antibody (Thermo Scientific) overnight at 4°C, 
followed by incubation with anti-goat lgG conjugated with Alexa Fluor 488 (Life 
Technologies) for detection of T-cadherin and anti-rabbit lgG conjugated with 
Alexa Fluor 594 (Life Technologies) for detection of adiponectin. DAPI was used 
as a nuclear stain. Images were recorded using Zeiss LSM 71 O-Live Duo scan 
confocal microscopy. 
Western blotting 
Gastrocnemius muscle and epididymal adipose tissue were harvested 
from 10 week-old male mice and snap frozen. Tissue was homogenized using 
RIPA buffer containing protease inhibitors and 100mM PMSF. Samples were 
centrifuged at 14,000rpm for 10 minutes. Protein concentration of supernatant 
was assessed by Pierce's bicinchoninic acid (BCA) assay. Serum or tissue 
lysate were resolved by SDS-PAGE and transferred to a PVDF membrane. 
Native western blots of the adiponectin isoforms were performed using non-
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reduced, non-denatured protein samples. Membranes were blocked with 5% 
nonfat milk in PBS + 0.1% Tween for 1 hour at room temperature. Primary 
antibody (1 :1 ,000) was added to the membrane overnight at 4°C in blocking 
buffer. Adiponectin (R&D Systems), T-cadherin (R&D Systems), tubulin (Santa 
Cruz), and J3-Actin (Cell Signaling) antibodies were used. The membrane was 
then incubated with secondary HRP-conjugated antibodies (1 :5,000) for 1 hour at 
room temperature and developed using SuperSignal West Pica 
Chemiluminescent Substrate (Pierce) and Amersham Hyperfilm (GE). 
Real-time qPCR 
RNA was isolated from HUVECs using the RNeasy Micro kit (Qiagen). 
RNA was isolated from epididymal adipose tissue and gastrocnemius muscle 
using RNeasy Plus Universal kit (Qiagen) and RNeasy Fibrous Tissue Mini kit 
(Qiagen), respectively. eDNA was synthesized from SOOng RNA with Superscript 
Ill First-Strand Synthesis System (Life Technologies). For HUVEC samples, 
Real Time PCR was performed using SYBR Green PCR Mastermix (Applied 
Biosystems). For tissue samples, Real-Time PCR was performed using Taqman 
PCR Mastermix. Expression of mRNA was determined forT -cadherin, AdipoR 1, 
AdipoR2, and adiponectin. Expression was normalized relative to GAPDH or J3-
Actin. 
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ELISA 
Blood was harvested from mice either by tail vein bleed or cardiac 
puncture. After clotting at room temperature, samples were centrifuged at 
7,000rpm and serum was isolated. Serum adiponectin concentration was 
determined by ELISA (B-Bridge) per the manufacturers' instructions. 
Mouse model of peripheral artery disease 
This model was developed by the Isner laboratory to non-invasively model 
revascularization over time under conditions of chronic ischemia88. Young 9-11 
week-old male mice were used in this study. In order to create unilateral hind 
limb ischemia a small incision was made in the upper portion of the hind limb of 
an anesthetized mouse (ketamine, 1 OOmg/kg and xylazine, 1 Omg/kg). Using a 6-
0 silk suture, a segment of the femoral artery was ligated and downstream 
collateral branches were severed. Finally, a small section of the ligated femoral 
artery, vein and nerve was excised. The wound was closed using surgical staples 
which remained in place for 10-14 days after surgery (Figure 11-1 ). 
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FIGURE 11-1. Hind limb ischemia surgical procedure. A) A small incision was made in the 
upper limb. B-F) Skin was removed from limb for illustrative purposes only. B) Femoral 
artery, vein and nerve were isolated using forceps. C) A silk suture was tied around the 
femoral artery, vein and nerve. D,E) Collateral vessels downstream of the ligation site were 
severed. F) Below the ligation, a segment of the femoral artery, vein and nerve were excised. 
G) The wound was closed using surgical staples. 
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Revascularization was measured and quantified using laser Doppler 
perfusion imaging. For Doppler measurements, mice were anesthetized and 
positioned under a scanning helium-neon laser beam, which penetrates to a 
depth of 600J.Jm. Blood cell movement in vessels shifts the frequency in the laser 
and the voltage of the back-scattered light is interpreted by the software as 
perfusion. In the output color images, dark blue indicates low blood flow while 
red indicates high flow. To control for environmental conditions such as 
variability in animal and/or room temperature, both ischemic and non-ischemic 
limbs are scanned for flow measurement. The flow value used for final 
interpretation is a ratio of the ischemic to non-ischemic limbs. Limb perfusion 
was monitored before surgery, immediately after surgery and at the following 
time points: day 3, day 7, day 14, day 21 and day 28. One limitation of this 
. technique is that animal fur interferes with blood flow measurement. Placing the 
mouse in a prone position allows for scanning of the hairless bottoms of the feet 
thus avoiding this interference89. Cream-based hair removal was used for scans 
of the top of the feet. 
Couffinhal, et al. measured Doppler blood flow in mice before surgery, 
immediately after surgery and at least once per week until day 3588. To validate 
the Doppler measurement as an appropriate surrogate measure of 
revascularization, mice were sacrificed at each Doppler time point and capillary 
density was measured in gastrocnemius muscle by immunohistochemical 
staining of CD31, an endothelial cell marker. Importantly, measurements of 
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Doppler ischemic/non-ischemic blood flow ratio correlated with the amount of 
CD31 (capillary) staining in the ischemic limb. Thus, increased perfusion as 
measured by laser Doppler imaging is due to revascularization of the tissue. 
Furthermore, the changes in blood flow measured at a depth of 6001Jm are 
representative of whole tissue vascularity based on capillary density88. 
Treadmill 
To assess limb function, at baseline and 10 days post-hind limb ischemia 
surgery, maximum treadmill running distance was determined. In order to 
acclimate to the equipment, mice were trained for 10 minutes prior to the start of 
the experiment. The trial began at a speed of 5 meters/minute. The belt speed 
was increased by 2 meters/minute every 5 minutes. The trial was stopped when 
mice were exposed to the electric stimulus at the rear of the treadmill for 30 
seconds. 
Score-based assessment of limb function 
At the time of laser Doppler measurement (post-surgical day 3), limb 
coloring and function were assessed by a modified version of a clinical scoring 
system90. A score of 0-4 was assigned to each mouse based on characteristics 
of the feet (0, normal function and coloring; 1, normal function and mild 
discoloration; 2, normal function and moderate discoloration; 3, impaired function 
and moderate discoloration; 4, impaired function and necrosis). 
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Cell Culture 
Human umbilical vein endothelial cells (HUVECs, ATCC) were cultured in 
EGM-2 media up to passage 6. Cells were transfected with 40nM siRNA 
(Dharmacon, siGENOME SMART Pool) and Lipofectamine RNAiMax (Life 
Technologies) for 72 hours. For the migration assay, cells were serum-depleted 
overnight in EBM-2 + 0.5% FBS. In a 6-well plate, confluent HUVECs were 
scratched with a 200~1 pipet tip and cultured for 16 hours in DMEM + 1% FBS ± 
1 01-Jg/ml recombinant full-length adiponectin protein (Biovendor). Cells were 
photographed at hours 0 and 16 to determine extent of migration, which was 
expressed as percent gap closure. To measure HUVEC proliferation, transfected 
cells were cultured in a 96-well plate. Growth media consisting of DMEM + 5% 
FBS ± 1 O~g/ml recombinant adiponectin protein was added 24 hours prior to the 
start of the BrdU incorporation assay. This BrdU ELISA-based assal1 was 
performed according to the manufacturer's instructions. 
Hydrodynamic Plasmid Delivery 
In some experiments, pLEV113-mADIPO-hFc (LakePharma), an 
adiponectin-Fc fusion construct (adiponectin plasmid), or pLEV113-MCS (control 
plasmid), were injected into mice 7 days prior to hind limb ischemia surgery. 
Adiponectin or control plasmid (241-Jg) was injected via the tail vein into restrained 
mice in 2.0-2.5ml total saline volume (10% of body weight) in 5 seconds 
according to a previously published protocol92. Mice were allowed to recover for 1 
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week before hind limb ischemia surgery. At the time of surgery, a small amount 
of blood was harvested by tail vein bleed for measurement of serum adiponectin 
by ELISA. 
Metabolic model and assessment 
Wild-type, AdipoR1-KO, and AdipoR2-KO female mice were fed a high 
fat/high sucrose diet (Bioserv, F1850) starting at 9-11 weeks-old and continuing 
for a total of 16 weeks. Mice were fasted overnight before sacrifice. Glucose 
and insulin tolerance tests were performed at 4, 8 and 12 weeks after the 
initiation of high fat/high sucrose diet feeding. For the glucose tolerance test, 
mice were fasted for 16 hours and baseline blood glucose was measured by the 
Accu-Chek A viva system. Glucose was administered by i.p. injection (1 gram of 
glucose/kg of body weight). Blood glucose was measured at the following time 
points: 15, 30, 60, 90, and 120 minutes after glucose injection. Mice were fasted 
for 6 hours prior to the start of the insulin tolerance test. An i.p. injection of 
insulin (0.6U insulin/kg body weight) was administered after measurement of 
baseline blood glucose levels. Glucose measurements were taken at 15, 30, and 
60 minutes post-injection. 
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Histology 
Gastrocnemius muscles were harvested, weighed and embedded in OCT 
compound. Sections (5t.Jm) were generated from the muscle tissue. 
Hematoxylin and eosin were used to stain the tissue using standard methods 
after fixing in cold acetone for 10 minutes. Immediately after sacrifice, liver tissue 
was incubated in 10% formalin overnight. Samples were dehydrated in a series 
of ethanol washes, treated with xylene and embedded in paraffin. Sections were 
cut at ?t.Jm, deparaffinized and then stained with hematoxylin and eosin. 
Statistical Analysis 
Data are presented as mean ± SEM. Analyses were performed using 
GraphPad Prism software. For LDPI analysis, a two-way repeated measured 
analysis of variance was performed with Bonferroni post-hoc tests. When 
directly comparing three or more groups, a one- or two-way analysis of variance 
was performed with post-hoc Student's t tests. A p value of less than 0.05 was 
considered statistically significant. 
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CHAPTER Ill 
T-CADHERIN IS ESSENTIAL FOR ADIPONECTIN-MEDIATED 
REVASCULARIZA TION 
T -cadherin localizes adiponectin to skeletal muscle tissue 
It has been previously reported that T -cadherin is important for binding 
and localizing adiponectin to tumor vasculature68 and cardiac tissue71 • To 
examine this activity in skeletal muscle, immunofluorescence analysis of murine 
gastrocnemius muscle was performed. Localization of adiponectin and T-
cadherin at the membranes of myocytes as well as capillaries was readily 
apparent in wild-type mice (Figure III-1A). Strikingly, adiponectin was not 
detected in the muscle of either adiponectin-deficient (APN-KO) mice or T-
cadherin-deficient (Tcad-KO) mice, suggesting that T-cadherin is required for its 
localization to these structures. Also of note, T -cadherin expression in muscle 
was markedly reduced in samples isolated from APN-KO mice. In contrast to 
these observations with the Tcad-KO mice, deficiency of AdipoR1 or AdipoR2 
had little or no effect on the localization of adiponectin to muscle tissue. 
Likewise, AdipoR1- or AdipoR2-deficiency had no apparent effect on T-cadherin 
expression. 
Western blot analysis of gastrocnemius muscle was performed to quantify 
levels of adiponectin and T -cadherin in the different experimental strains of mice 
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(Figures 111-1 8-D). As expected, adiponectin was not detected in the muscle of 
APN-KO mice. Similar to the immunohistochemical analysis, adiponectin protein 
was not detected in muscle lysates from Tcad-KO mice (Figures III-1B,C). 
Similarly, tissue levels of T-cadherin were reduced in APN-KO mice (Figures 111-
1 B,D), suggestive of a feedback regulatory loop between adiponectin and T-
cadherin. Muscle T -cadherin is detected as a double band representing the 
mature and pro-peptide forms of the protein59. Adiponectin-deficiency led to 
reduction in the expression of both forms, with nearly complete disappearance of 
the higher molecular weight, pro-peptide containing isoform (Figure 111-1 B). 
Similar levels ofT -cadherin mRNA expression in gastrocnemius muscle isolated 
from wild type and APN-KO mice were observed (Figure III-1E), indicating that 
the regulation ofT -cadherin is post-transcriptional. 
Consistent with a decrease in tissue-localized adiponectin, mice deficient 
in T -cadherin have elevated levels of circulating, unbound serum adiponectin 
(Figure 111-1 F). By western blot analysis, it appears that the high molecular 
weight (HMW) isoform of adiponectin is selectively elevated in the serum of 
Tcad-KO mice (Figure III-1G). This observation supports the notion that T-
cadherin preferentially binds the HMW isoform93. As expected, serum 
adiponectin protein was not detected by ELISA or western blot in adiponectin-
deficient mice. Despite markedly elevated adiponectin levels in the serum of the 
Tcad-KO mice, adipose tissue levels of adiponectin transcript and protein are 
unaffected by T-cadherin deficiency (Figures 111-1 H-K). Furthermore, adiponectin 
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mRNA expression in muscle was negligible compared with that of adipose tissue 
and did not differ between groups. Also of note, the distribution of adiponectin 
isoforms in adipose tissue is not different between wild type and Tcad-KO mice 
(Figure III-1K). Taken together, these data suggest that T-cadherin is critical for 
tissue localization of adiponectin, and that the elevated circulating adiponectin 
found in the Tcad-KO mouse results from its liberation from tissue rather than an 
increase in its synthesis. 
T -cadherin is required for limb revascularization 
Due to the dependence of adiponectin tissue localization on T -cadherin 
expression and the dependence ofT -cadherin expression on adiponectin levels, 
further studies were performed to determine the functional significance of the 
protein-protein interaction in a model of peripheral artery disease. Wild-type, 
APN-KO, and Tcad-KO mice underwent analysis in a model of unilateral hind 
limb ischemia where a small segment of the femoral artery, nerve and vein was 
ligated and excised. Limb perfusion was then monitored for 28 days using LDPI. 
Impaired recovery of the laser Doppler signal was observed in both adiponectin-
deficient and Tcad-KO mice relative to isogenic wild-type mice (Figures III-2A-B). 
Statistically significant reductions in LDPI were observed at 7, 14, 21 and 28 day 
time points. At the time of surgery (9-11 weeks old), male APN-KO and Tcad-KO 
mice were of similar body weight to WT mice and did not exhibit metabolic 
abnormalities under the conditions of our assays (Figures A-1 A-C) as previously 
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FIGURE 111-1. T -cadherin localizes adiponectin to skeletal muscle tissue. A) 
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AdipoR2 KO mice. DAPI was used as a nuclear stain . 
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reported for young Tcad-KO mice94. Metabolic dysfunction and decreased body 
weight were observed in older Tcad-KO mice (22 weeks) fed a chow or high 
fat/high sucrose diet (Figure A-2A-D). 
A common clinical assessment of limb function in patients with peripheral 
artery disease is walking distance on a treadmi1195. Thus, to assess functional 
recovery from hind limb ischemia, mice were subjected to treadmill running until 
exhaustion at 10 days post-surgery. Whereas, no difference in running ability 
between strains was detected at baseline (Figure III-2C), after chronic ischemia 
APN-KO and Tcad-KO mice displayed reduced maximum treadmill running 
distance compared to wild-type mice (Figure 111-20). Wild type mice equally 
utilized both limbs for running, while APN-KO and Tcad-KO mice favored their 
non-ischemic limb. Collectively, these data show that the decreases in 
reperfusion, as assessed by LDPI, in APN-KO and Tcad-KO mice correspond to 
functional limitations in limb performance. These data also show that APN-KO 
mice and Tcad-KO mice display similar phenotypes with regard to their 
revascularization response to chronic ischemia. 
T -cadherin is essential for adiponectin-mediated revascularization 
We have previously reported that elevating levels of serum adiponectin by 
adenoviral overexpression rescues the impaired blood flow recovery of 
adiponectin-deficient mice in the hind limb ischemia model96 . 
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32 
Thus, to determine causality for a functional interaction between T -cadherin and 
adiponectin, an in vivo rescue experiment was performed via the expression of 
exogenous adiponectin. As detailed in Figures 111-1 F,G, Tcad-KO mice have 
higher levels of serum adiponectin than wild-type mice at baseline. As high 
baseline levels of adiponectin would confound an adiponectin rescue experiment 
in the Tcad-KO mice, a strain that was deficient in both T-cadherin and 
adiponectin (TA-dKO) was prepared for this purpose. Thus, the rescue of 
adiponectin-null mice can be directly compared in APN-KO and TA-dKO mice. 
As described previousll1, TA-dKO mice are viable and breed with normal 
Mendelian frequency. 
Adiponectin was administered to APN-KO and TA-dKO mice using 
hydrodynamic delivery of a plasmid vector that expresses murine adiponectin 
(pLEV113-mADIPO-hFc). In this procedure, the plasmid is rapidly delivered in a 
0.9% saline solution via tail vein injection. This results in the efficient 
transduction of hepatocytes that express the protein of interest92·97 . One week 
after hydrodynamic injection, mice were subjected to hind limb ischemia surgery. 
At the time of surgery, blood was collected by tail vein to determine the 
concentration of serum adiponectin. Adiponectin levels were undetectable in 
control plasmid-injected APN-KO and TA-dKO mice (Figure III-3A). 
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The impaired revascularization response observed in TA-dKO mice 
injected with control plasmid was not different from that of APN-KO or Tcad-KO 
mice injected with control plasmid. Deficiency of both adiponectin and T-
cadherin did not exacerbate the impairment in revascularization beyond that of 
the single KO mice. APN-KO mice injected with adiponectin plasmid reached 
physiological levels of adiponectin one week after treatment (Figure III-3A). As 
anticipated, replenishment of adiponectin improved blood flow recovery in 
adiponectin-deficient mice (Figures 111-38,0). However, adiponectin delivery did 
not improve blood flow recovery in TA-dKO mice (Figures III-3C,D). These data 
suggest that expression ofT -cadherin is required for the revascularization 
actions of adiponectin in the hind limb ischemia model. 
T -cadherin is required for adiponectin-induced migration and proliferation 
of endothelial cells 
Revascularization as a result of chronic ischemia is largely due to an 
adaptive angiogenesis and/or arteriogenesis response involving endothelial cell 
migration and proliferation98. Thus, cell culture experiments were initiated to 
further delineate the functional relationship between T -cadherin and adiponectin. 
It has been previously reported that adiponectin promotes endothelial cell 
migration and proliferation in vitro47•99•100. Thus, the dependence of adiponectin's 
in vitro angiogenic activities on T -cadherin expression in endothelial cells was 
36 
A 
8 
~ 1.25 
c: 
.2 1.00 
Ill 
Ill 
~ 
~ 0. 
w 
~ 
0::: 
E 
40 
O....L..IL..-...--....L..-
rAPN 
siRNA 
2.0 
Control 
c i 
~ 1.5 
~ 
~ 
g_ 1.0 
.... 
0 
u 
.= 
:J 0.5 
"C 
.... 
m 
O.O....L..IL..-...--....L..-
rAPN 
siRNA Control 
+ 
+ 
+ 
T-Cadherin 
+ 
T-Cadherin 
~ Control siRNA 
- T-Cadherin siRNA 
FIGURE 111-4. siRNA knockdown of T -cadherin blocks adiponectin-induced migration 
and proliferation of endothelial cells in vitro. A) mRNA expression of T-cadherin . 
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evaluated. Using low passage HUVECs treated with siRNA transfection 
reagents, T-cadherin mRNA expression was reduced by >85%. The expression 
of other reported adiponectin binding proteins, AdipoR1 and AdipoR2, was not 
altered by knockdown of T-cadherin (Figure III-4A). In a scratch-induced 
migration assay, knockdown of T-cadherin had little or no effect on HUVEC 
migratory activity. The addition of recombinant adiponectin (rAPN) promoted 
migration in cells transfected with control siRNA but not in those that received T-
cadherin-targeting siRNA (Figure 111-48). In an assay of HUVEC proliferation, 
knockdown ofT -cadherin had a small effect on BrdU incorporation into DNA. 
Notably, adiponectin-induced proliferation was not observed in HUVECs deficient 
in T -cadherin (Figure III-4C). These data show that expression ofT -cadherin is 
required for the ability of adiponectin to promote endothelial cell migration and 
proliferation in vitro. 
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CHAPTER IV 
DIVERGENT ROLES FOR ADIPOR1 AND ADIPOR2 
IN MEDIATING REVASCULARIZATION AND METABOLIC DYSFUNCTION 
Differential effects of AdipoR1 and AdipoR2 on limb revascularization 
We have previously reported that adiponectin-deficient mice display 
impaired revascularization in a model of chronic hind limb ischemia. To identify a 
functional receptor for adiponectin in the vasculature, hind limb ischemia surgery 
was performed on mice deficient in AdipoR1 or AdipoR2 and their wild-type 
littermates. During this procedure, blood flow was disrupted in one limb and 
recovery was monitored by laser Doppler perfusion imaging52•53. AdipoR1-KO 
mice recovered Doppler limb perfusion at a similar rate as wild-type mice (Figure 
IV-1A). After 28 days, both wild-type and AdipoR1-KO mice recovered 70-75% 
of blood flow in their ischemic limb (Figure IV-1 B). In contrast, AdipoR2-KO mice 
had notably delayed recovery and flow improvement was not detectable until 14 
days after induction of ischemia. Limb retraction and atrophy in AdipoR2-KO 
mice are visible in the laser Doppler image (Day 14, Figure IV-1C). Due to the 
severe limb ischemia observed, approximately 30% of the AdipoR2-KO mice had 
to be euthanized by day 14 post-surgery per veterinarian recommendations. 
AdipoR2-deficient mice displayed significantly impaired blood flow recovery 
compared with their littermate controls (Figure IV-1 D). 
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AdipoR2-deficient mice exhibit limb necrosis and impaired function 
following hind limb ischemia surgery. 
In wild-type mice, toe necrosis is rare and limb function appears normal 3 
days after hind limb ischemia surgery. In contrast, limb necrosis was observed in 
over 70% of AdipoR2-KO mice as early as 3 days after surgery (Figure IV-2A). 
AdipoR2-KO mice were functionally impaired following surgery and were 
observed dragging the ischemic limb while walking. In contrast, wild-type mice 
utilize both their ischemic and non-ischemic limbs equally and were capable of 
lifting and pushing off of either foot. By day 7, the necrosis observed in AdipoR2-
KO mice can extend past the toe nail and throughout the toes (Figure IV-2A). In 
some AdipoR2-KO mice, the foot completely necroses leading to auto-
amputation. These observations were semi-quantitatively expressed at day 3 
post-surgery by use of a scoring system where a higher score indicates more 
severe discoloration (necrosis) and loss of ischemic limb function. Scores taken 
at an early time point are predictive of long-term blood flow recovery90. 
Consistent with the laser Doppler imaging analysis, no difference was detected 
between wild-type and AdipoR1-KO mice, whereas AdipoR2-deficient mice, 
marked by frequent necrosis and impaired limb function, had a significantly 
higher score compared to wild-type controls (Figure IV-28). 
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Gastrocnemius muscle was harvested from wild-type, AdipoR1-KO and 
AdipoR2-KO mice 28 days after hind limb ischemia surgery to determine tissue 
weight and composition. In the hind limb ischemia model it is typical to observe 
ischemic muscle swelling (day 3), followed by atrophy (day 7) and ultimately 
recovery to 85-90% of the non-ischemic limb weight (day 28). While we 
observed this trend in wild-type and AdipoR1-KO mice, muscle atrophy remained 
unresolved in AdipoR2-KO mice (Figure IV-2C). In wild-type mice, hematoxylin 
and eosin-stained gastrocnemius muscle sections generally have a centralized 
region of necrotic tissue surrounded by infiltrating inflammatory cells 3 days post-
hind limb ischemia surgery. At days 7 and 14, vasculature and muscle 
regeneration occur and nascent myocytes, identified by their centralized nuclei, 
are abundant. By day 28, necrosis is resolved, nascent myocytes are rare and 
few inflammatory cells remain in wild-type tissue. Immunohistochemical analysis 
revealed widespread necrosis in AdipoR2-deficient skeletal muscle at day 28. In 
contrast to wild-type tissue, the majority of myocytes present in AdipoR2-KO 
tissue are nascent (Figure IV-20). Strikingly, AdipoR2-KO skeletal muscle has a 
significant amount of acellular area containing cell debris and residual 
inflammatory infiltrate. These data describe an attenuated skeletal muscle 
regenerative response in AdipoR2-deficient mice. 
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AdipoR2 is necessary for the revascularization actions of adiponectin 
To define causality for a ligand-receptor functional interaction between 
adiponectin and AdipoR2, we determined if treatment with exogenous 
adiponectin would rescue the impairment in blood flow recovery in AdipoR2-KO 
mice. We have previously reported that treatment with adenovirus-expressing 
adiponectin promotes blood flow recovery in wild-type mice subjected to hind 
limb ischemia96. In the current study, we employed the hydrodynamic method to 
deliver a plasmid-encoding adiponectin or a control plasmid. Wild-type and 
AdipoR2-KO mice were treated one week prior to hind limb ischemia surgery and 
blood flow recovery was monitored for 14 days. No significant difference was 
detected in baseline serum adiponectin between wild-type and AdipoR2-KO 
mice. Treatment with adiponectin plasmid increased circulating levels of 
adiponectin by 2-fold in both wild-type (Figure IV-3A) and AdipoR2-KO mice 
(Figure IV-3D). 
As anticipated, blood flow recovery was improved in adiponectin-treated 
wild-type mice compared to control-treated wild-type mice (Figure IV-38). At 14 
days post-surgery, the ischemic limb of control-treated wild-type mice showed 
50% blood flow recovery compared to the non-ischemic limb. Adiponectin-
treatment accelerated this recovery to 70% of control (Figure IV-3C). However, 
under conditions of AdipoR2-deficiency, adiponectin treatment did not promote 
revascu\arization activity. No difference in Doppler blood flow was observed 
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FIGURE IV-3. AdipoR2 is necessary for the revascularization actions of adiponectin. 
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harvested at the time of surgery. Mean ± SEM. n = 6-9. *p < 0.05 vs. control delivery. 
B) Representative Doppler images pre-surgery (Pre), immediately post-surgery (Post) and 14 
days post-surgery. C) Laser Doppler perfusion analysis of wild-type mice receiving control or 
adiponectin plasmid delivery. Mean± SEM, n = 6-9, *p < 0.05. 
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47 
between the ischemic limbs of control and adiponectin-treated AdipoR2-deficient 
mice (Figure IV-3E). Compared with the non-ischemic limb, blood flow recovery 
in the ischemic limbs of AdipoR2-KO mice did not exceed 25% in either 
treatment group (Figure IV-3F). Taken together, these data suggest that 
expression of AdipoR2 is essential for adiponectin-mediated revascularization. 
High fat/high sucrose diet induces metabolic dysfunction in AdipoR1-
deficient mice. 
The importance of AdipoR1 and AdipoR2 in mediating the metabolic 
actions of adiponectin remains controversial33•84•87. Since we observed a 
divergent role for AdipoR1 and AdipoR2 in the vascular actions of adiponectin, 
the metabolic consequences of eliminating AdipoR1 or AdipoR2 were examined. 
At baseline, AdipoR1-deficient mice were slightly heavier while AdipoR2-deficient 
mice had a reduced body weight compared with wild-type mice (Figures A-3A,D). 
Importantly, no differences in glucose tolerance (Figures A-3B,E) or insulin 
sensitivity were detected among the groups at baseline (Figures A-3C,F). 
AdipoR1-KO and wild-type littermate controls were fed a high fat/high sucrose 
diet for 16 weeks starting at 9-11 weeks of age. After only 4 weeks of high 
fat/high sucrose diet, AdipoR1-KO mice exhibited significantly elevated body 
weight compared with wild-type littermate controls (Figure A-4A). Following 
acute administration of glucose, wild-type mice cleared glucose more efficiently 
than AdipoR1-KO mice (Figure A-4C). 
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The increased body weight and impaired glucose tolerance observed in 
AdipoR 1-KO mice persisted and became worsened after 8 weeks (Figures A-
48,0) and 12 weeks on diet (Figures III-4A,B). Following injection of insulin, the 
effect on blood glucose levels was initially similar between groups (Figures A-
4E,F). However, after 12 weeks of high fat/high sucrose diet, AdipoR1-KO mice 
displayed impaired responsiveness to insulin compared to wild-type mice. 
Following an acute administration of insulin, serum glucose levels declined at a 
slower rate in AdipoR1-deficient mice (Figure IV-4C). Metabolic tissues such as 
adipose, muscle, and liver were harvested and weighed at the time of sacrifice. 
Gastrocnemius muscle weight was comparable between groups. AdipoR1-
deficient mice had increased reproductive white adipose tissue, brown adipose 
tissue, and liver weight compared to wild-type littermates (Figures IV-4D-G). 
Upon closer inspection, lipid droplets were more abundant in hematoxylin and 
eosin-stained liver sections of AdipoR1-deficient mice (Figure IV-4H). The 
observed increases in liver weight and lipid accumulation in AdipoR1-KO mice 
indicate development of hepatic steatosis. In summary, AdipoR1-KO mice are 
more susceptible to diet-induced obesity complications including expansion of 
adipose depots, glucose intolerance, insulin resistance, and fatty liver. 
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AdipoR2-deficient mice are protected from diet-induced weight gain and 
metabolic dysfunction. 
In contrast to AdipoR1-KO mice, AdipoR2-KO mice were resistant to high 
fat/high sucrose diet-induced weight gain after 4 and 8 weeks on diet (Figures A-
5A,B). Glucose tolerance test (Figures A-5C,D) and insulin tolerance test 
(Figures A-5E,F) performance was not different between AdipoR2-KO mice and 
wild-type littermate controls after 4 and 8 weeks on high fat/high sucrose diet. 
AdipoR2-KO mice remained significantly lighter than wild-type mice after 12 
weeks of diet (Figure IV-5A). At this time point, AdipoR2-deficient mice had 
significantly improved clearance of blood glucose (Figure IV-58). In addition, 
tissue responsiveness to insulin in AdipoR2-KO mice was superior to that of wild-
type mice (Figure IV-5C). Consistent with these data, weights of reproductive 
white adipose tissue, brown adipose tissue, gastrocnemius muscle and liver 
tissue were significantly less than littermate controls (Figures IV-5D-G). 
AdipoR2-deficient mice had improved parameters following exposure to high 
fat/high sucrose diet including enhanced glucose tolerance and insulin sensitivity, 
resistance to weight gain and slightly reduced lipid accumulation in liver tissue 
compared with wild-type littermate controls (Figure IV-5H). A strong divergent 
role for the adiponectin receptors, AdipoR1 and AdipoR2, is not only apparent in 
recovery from hindlimb ischemia surgery, but also in diet-induced metabolic 
dysfunction. 
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CHAPTERV 
DISCUSSION 
T-cadherin 
Adiponectin is almost exclusively produced by adipose tissue, and it acts 
on cardiovascular tissues in a paracrine manner. While it is widely recognized 
that adiponectin has vascular-protective and pro-angiogenic actions, the 
membrane proteins that mediate these actions are unknown. Here, we assessed 
the functional interaction between adiponectin and T -cadherin, a GPI-anchored 
membrane protein, using both in vitro and in vivo assays. Our findings show that 
T -cadherin is required for localization of adiponectin to skeletal muscle, and that 
Tcad-KO mice are phenotypically similar to APN-KO mice in that both strains 
display impaired blood flow recovery compared with wild-type mice in a model of 
hind limb revascularization. The impaired revascularization phenotype could be 
rescued by the administration of adiponectin in APN-KO mice but not in mice that 
were lacking T-cadherin. These studies confirm the critical role ofT -cadherin in 
ischemia-induced revascularization, and are the first to demonstrate that T-
cadherin functions are essential in mediating the pro-angiogenic activity of 
adiponectin. 
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We report that adiponectin is present on the cell surfaces of the vascular 
endothelium and myocytes in gastrocnemius muscle tissue of wild-type mice. 
However, adiponectin localization is not detected in the muscle of Tcad-KO mice. 
Based upon these data, it is reasonable to hypothesize that T -cadherin facilitates 
the ability of adiponectin to promote vascular function through its localization of 
this adipokine to target tissues. Consistent with these observations, it has also 
been reported that T -cadherin is important for the localization of adiponectin to 
tumor vasculature 58 and the heart71 . Adiponectin is abundantly present in the 
serum of wild-type mice, but its levels in serum are elevated -4-fold in mice that 
lack T-cadherin. Since the expression of adiponectin protein and transcript by 
adipose tissue is not influenced by a deficiency in T -cadherin, it would appear 
that approximately 75% of the organism's total adiponectin is bound to tissue via 
a T-cadherin-dependent mechanism. In contrast to T-cadherin, the localization of 
adiponectin to skeletal muscle tissue was not dependent on expression of either 
AdipoR1 or AdipoR2. Thus, while AdipoR1 may have important metabolic effects 
in skeletal muscle85·86· 101 , it appears that T -cadherin is primarily responsible for 
binding and localizing adiponectin to that tissue. Furthermore, based upon these 
data, the presence of AdipoR 1 and AdipoR2 is not sufficient to enable a 
revascularization response to the administration of adiponectin. 
Further evidence of a functional T-cadherin-adiponectin interaction comes 
from the observation that T -cadherin protein expression in skeletal muscle is 
markedly repressed in APN-KO mice. In contrast, T -cadherin mRNA expression 
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is not altered in APN-KO mice compared with wild type, indicating that this 
regulation is post-transcriptional. Denzel, et al. also observed the coordinate 
regulation of adiponectin and T -cadherin expression in hearf1. Similarly, a 
correlation between adiponectin and T -cadherin expression was described in a 
model of liver fibrosis where elevated serum adiponectin was associated with 
elevated hepatic expression ofT -cadherin 102. Thus it is tempting to speculate 
that adiponectin signals through T -cadherin to support T -cadherin's expression 
via a positive feedback loop mechanism. Accordingly, altered expression ofT-
cadherin under physiological or pathological conditions could then lead to 
changes in the amounts of circulating and tissue-localized adiponectin. 
Adiponectin is an unusual receptor ligand because it circulates at very 
high levels and has a complex structure. In humans, adiponectin levels in serum 
range from 3 to 30j.Jg/ml, and it represents approximately 0.01% of the total 
serum protein 103 . In contrast, growth factors and cytokines that interact with 
conventional cell surface receptors are present in the circulation at levels that are 
three orders of magnitude lower. Adiponectin is comprised of a globular head 
and a collagenous tail that allow the protein to form stable trimers, hexamers, 
and higher order oligomers (360-540kDa). These properties suggest that 
adiponectin is structurally and functionally similar to collectin proteins that interact 
with a variety of macromolecules at relatively low affinities. Collectin proteins, 
such as C1q and lung surfactant proteins, either circulate at high levels or are 
localized to mucosal surfaces in the lung and gastrointestinal tract where they 
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function to protect tissues from environmental stress104·105 . Accordingly, 
collectin-like properties have been attributed to adiponectin, including an ability to 
opsonize apoptotic cells21 and bind bacterial lipopolysaccharides22. On the other 
hand, it is also clear that adiponectin can activate intracellular signaling cascades 
that control cellular phenotype47•52 suggesting that these effects are mediated by 
specific receptors on the cell surface. However, given its structure and 
abundance, it is likely that adiponectin's receptor interactions will be atypical. In 
particular, it is difficult to imagine a classical, high affinity ligand-receptor 
interaction for adiponectin because the receptor would be in a constant state of 
saturation at physiological levels of this adipokine. In view of these 
considerations, T -cadherin may serve as a membrane-associated signal 
transducer for adiponectin. Like adiponectin, T -cadherin is abundantly present 
on the surface of some cell types, and it may serve as a low-affinity receptor for 
adiponectin. Alternatively, T-cadherin may have a co-receptor function and be 
required for the proper presentation of adiponectin to a classical high-affinity 
receptor, such as AdipoR1 or AdipoR2. 
While it is clear that T -cadherin localizes adiponectin to various tissues, it 
is not well understood how T -cadherin initiates intracellular signaling since it 
lacks a transmembrane and intracellular domain. However, it has been reported 
that T-cadherin can function independently of adiponectin by promoting LDL-
induced intracellular calcium release 106, facilitating release of insulin from 
pancreatic l3-cells94 , and inhibiting insulin signaling in endothelial cells via 
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P13K/Akt/mTOR axis70 . Since T-cadherin is found to co-localize with caveolin, it 
is possible that interactions between T -cadherin and other proteins in caveolae or 
lipid rafts may also result in intracellular signaling 107. This concept of receptor 
internalization is consistent with a report ofT -cadherin nuclear localization in 
endothelial cells 108. T-cadherin has been shown to promote endothelial survival 
via direct interactions with integrin-linked kinase 109 and Grp78110. However, 
these studies did not evaluate T-cadherin signaling downstream of adiponectin, 
nor a functional relationship between T-cadherin and AdipoR1 and/or AdipoR2. 
Recently, Denzel et al. identified T -cadherin as critical for the cardiac-
protective effects of adiponectin in models of cardiac hypertrophy and ischemia-
reperfusion71. Taken together with the current study, this work highlights the 
critical role forT -cadherin in mediating the protective effects of adiponectin in the 
cardiovascular system. On the other hand, studies in models of asthma 111 ·112 
and acute lung injury 113 indicate that the effects of adiponectin in the lung may be 
independent ofT -cadherin. In fact, mice deficient in T -cadherin are protected 
from these acute inflammatory insults relative to wild-type mice, whereas APN-
KO mice display a worsened phenotype. 
Peripheral artery disease is a serious condition of reduced lower limb 
perfusion that is estimated to affect 15-20% of the elderly population48 . The 
development of peripheral artery disease is associated with smoking, advanced 
age and metabolic syndrome, and it represents a major unmet clinical need 114. 
Our results suggest that adiponectin has therapeutic benefit for ischemic limb 
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disease and that this effect occurs via an interaction with T -cadherin. Consistent 
with this hypothesis, it is reported that circulating levels of HMW adiponectin are 
inversely associated with development of peripheral artery disease 54. Moreover, 
genome wide association studies have linked T -cadherin with peripheral artery 
disease risk factors and co-morbidities75·81 '115. Interestingly, polymorphisms in 
the T -cadherin gene are also associated with circulating levels of adiponectin in 
human subjects72-77, and these reports are reminiscent of observations made 
here of elevated serum adiponectin levels in Tcad-KO mice. Collectively, these 
findings highlight the importance of the T -cadherin-adiponectin interaction in 
vascular homeostasis and suggest that further studies on this system could lead 
to a better understanding of ischemic diseases. 
AdipoR1 and AdipoR2 
Here, we evaluated AdipoR1 and AdipoR2 as candidate receptors for 
mediating the protective vascular actions of adiponectin. Although the genetic 
mouse models were generated almost 6 years ago33•84, this is the first study to 
evaluate AdipoR1-KO and AdipoR2-KO mice in an in vivo cardiovascular model. 
Our lab has previously found that mice lacking adiponectin display impaired 
revascularization in a model of peripheral artery disease. We found that 
AdipoR1-deficiency did not alter the blood flow recovery response compared to 
wild-type littermate controls. Strikingly, AdipoR2-KO mice developed marked 
necrosis and loss of limb function following hindlimb ischemia surgery. 
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Administration of exogenous adiponectin significantly improved blood flow 
recovery in wild-type mice but failed to rescue the impaired phenotype of 
AdipoR2-KO mice. Taken together, these results indicate that expression of 
AdipoR2 but not AdipoR1 is essential for the revascularization actions of 
adiponectin. 
Recently, two studies have implicated adiponectin in cutaneous wound 
healing, the impairment of which is a common complication of diabetes 116•117. 
Adiponectin promotes wound healing through the enhanced proliferation and 
migration of keratinocytes. siRNA knockdown of AdipoR 1 or AdipoR2 in vitro 
prevented adiponectin-induced signaling in these cells 116. Treatment with 
adiponectin protein in vivo promoted wound healing in wild-type mice but its 
protective actions were lost in AdipoR1-KO mice117. AdipoR2-KO mice have 
never been tested in an in vivo model of cutaneous wound healing, thus the 
physiological importance of AdipoR2 expression cannot be excluded. 
In this study, we also confirmed a divergent role for the adiponectin 
receptors in a mouse model of metabolic dysfunction. A previous report by Liu, 
et al. examined AdipoR2-KO mice and found they were resistant to weight gain 
after 8 weeks of high-fat feeding. Consistent with the results presented here, 
AdipoR2-deficiency was metabolically protective such that the diet-induced 
glucose intolerance and insulin insensitivity observed in wild-type mice was 
attenuated in AdipoR2-KO mice87. Two reports compared independently 
generated strains of AdipoR1-KO and AdipoR2-KO mice33•84. Yamauchi, et al. 
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reported no differences in body weight among AdipoR1-KO mice, AdipoR2-KO 
mice and littermate controls. However, both AdipoR 1-KO mice and AdipoR2-KO 
mice developed glucose intolerance after 8 weeks of high fat/high sucrose diet 
feeding33. Bjursell, et al. observed that AdipoR1-KO mice exhibited increased 
body weight and glucose intolerance while AdipoR2-KO mice were resistant to 
diet-induced weight gain and displayed improved glucose tolerance compared to 
wild-type controls84. The latter findings mirror those reported here. In a model of 
diet-induced obesity AdipoR 1-deficiency resulted in increased weight gain and 
exacerbated metabolic dysregulation while AdipoR2-deficient mice were 
metabolically protected with reduced weight gain. Caution must be taken in 
directly comparing these studies due to variations in mouse model generation, 
mouse gender, testing conditions, duration of diet and composition of high 
fat/high sucrose diet among the laboratories. 
In both mouse models of peripheral artery disease and metabolic 
dysfunction, the phenotypes of AdipoR2-KO mice and AdipoR1-KO mice, 
respectively, are exacerbated compared with that of adiponectin-deficiency. In 
other words, the receptor-deficiency has a greater phenotypic effect than the 
ligand-deficiency. In the model of hind limb ischemia, adiponectin-deficient mice 
have impaired blood flow recovery but rarely develop necrosis. Foot necrosis 
occurred in almost three-quarters of AdipoR2-KO mice tested. By day 7, APN-
KO mice recover Doppler flow to 32% of the non-ischemic limb (Figure 111-28) 
while ischemic limbs of AdipoR2-KO mice display only 1 0% of control blood flow 
60 
(Figure IV-1 D). Using our model of high fat/high sucrose diet-induced obesity, we 
did not detect differences in weight gain, glucose tolerance or insulin sensitivity 
between wild-type and adiponectin-deficient mice at any time point (data not 
shown). This is consistent with some findings 118 and yet contradictory with 
others11 ·119·120. Dramatic differences in duration of high fat/high sucrose diet 
alone preclude direct comparisons between these studies. It is possible that the 
in vivo consequences of adiponectin deficiency are diminished by a 
compensatory mechanism involving the upregulation of other anti-inflammatory 
adipokines. 
Although termed adiponectin receptors 1 and 2, these transmembrane 
proteins may have adiponectin-independent actions. For example, AdipoR 1 or 
AdipoR2 may have constitutive functions or bind other ligands in addition to 
adiponectin. The C1q/TNF-related proteins (CTRPs) share structural and 
functional similarity with adiponectin. A recent in vitro study found that 
expression of AdipoR1 is important for the actions of CTRP9 in endothelial 
cells 121 . Adiponectin receptor interacting proteins (adaptor protein containing 
pleckstrin homology domain, phosphotyrosine binding domain and leucine zipper 
motif 1 and 2, APPL 1 and APPL2) also have an essential role in conferring 
differential adiponectin signaling responses 132. For example, overexpression of 
APPL2 reduces adiponectin-mediated signaling through the AdipoR1-APPL 1 axis 
in skeletal muscle 122·123. Other adiponectin receptor-interacting molecules 
including receptor of activated kinase 1 (RACK1 )124, protein kinase CK2f3125, 
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endoplasmic reticulum protein 46 (ERp46)126, and caveolin-3127 may affect 
signaling downstream of adiponectin and its receptors. 
AdipoR 1 and AdipoR2 heteromers and homomers have been 
identified128•129, therefore, adiponectin-mediated effects on vascular and 
metabolic homeostasis may be dependent on expression of both AdipoR 1 and 
AdipoR2. Upon binding adiponectin, the dimeric receptor configurations 
disassemble into monomers, internalize and are ultimately recycled back to the 
plasma membrane. Consistent with previous findings, receptor responses 
differed depending on whether globular or full-length adiponectin isoforms were 
administered. A recent report suggests that the non-conserved N-terminal 
regions of AdipoR1 and AdipoR2 may affect their cell-surface expression 130 . 
Interestingly, AdipoR2 membrane localization in vitro was dependent on 
expression of AdipoR 1130. This suggests that in the absence of AdipoR 1, 
localization of AdipoR2 is restricted to intracellular organelles such as the 
endoplasmic reticulum. Our findings of an impaired revascularization response 
in AdipoR2-KO mice are not replicated by AdipoR1-deficiency. It is possible that 
in vivo AdipoR2 is expressed on the plasma membrane in the absence of 
AdipoR 1 through a stabilizing interaction with another membrane-localized 
protein. Future characterization of the receptor-mediated actions of adiponectin 
in the cardiovascular and metabolic systems may reveal a novel therapeutic 
target. 
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Adiponectin resistance 
Decreased adiponectin expression, as observed in obese individuals, is 
associated with an increased risk of metabolic and cardiovascular disease. 
Recent studies have found an association between high adiponectin levels and 
mortality. This suggests a J-shaped curve for adiponectin concentration such 
that lean, healthy individuals have high adiponectin, patients at risk for 
development of disease have reduced adiponectin, and patients with end-stage 
organ failure (i.e. heart failure 131 ·132, respiratory failure 133 and renal failure 134) 
have elevated adiponectin. It is not known why levels of adiponectin increase in 
these very sick patients but the elevation is associated with a greater risk of 
mortality. Two popular hypotheses are that either elevated serum adiponectin is 
a late compensatory response or that adiponectin is no longer able to exert its 
protective functions. The mechanism for this 'adiponectin resistance' is unknown 
but one could postulate that it is due to decreased expression and/or signaling of 
the adiponectin receptors. 
A recent study has identified a serum form ofT -cadherin which is 
associated with endothelial microparticles 135. Patients with atherosclerosis had 
both increased T -cadherin protein expression in the atherosclerotic plaque and in 
serum. Serum levels ofT -cadherin were correlated with endothelial dysfunction 
as measured by reactive hyperaemia-peripheral arterial tonometry. Since 
chronic heart failure patients have elevated serum adiponectin 131 , expression of 
T-cadherin was measured in heart tissue and serum. Surprisingly, heart failure 
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patients with either dilated cardiomyopathy (DCM) or ischemic cardiomyopathy 
(ICM) have increased expression ofT -cadherin protein in heart tissue compared 
with control patients (Ali EI-Armouche, unpublished data). Serum T -cadherin 
levels did not differ between heart failure and control subjects. As with the C1q-
adiponectin serum complex25, it is not known what fraction of serum adiponectin 
is bound by soluble proteins. The function and stability of such adiponectin-
protein interactions should be investigated. 
Study Limitations 
Important limitations must be considered with use of whole body knockout 
model. First, since the gene expression has been absent during development, 
compensatory responses involving up- or down-regulation of other genes are 
possible. Second, while we may conclude that a secreted protein has a 
physiological or pathological role, the cellular source and action sites may be 
difficult to elucidate. These limitations may be overcome by inducing gene 
knockout after development and restricting the deletion (or overexpression) to a 
single cell type. For example, a mouse with floxed alleles of an adiponectin or 
adiponectin receptor gene may be crossed to a mouse expressing tamoxifen-
inducible ere recombinase in endothelial cells 136. Previous in vitro studies by our 
lab identified CRT and LRP1 as receptors important for adiponectin-mediated 
clearance of apoptotic cells21 and endothelial cell signaling53 . The in vivo 
revascularization roles of these candidate adiponectin receptors cannot be 
64 
excluded. As the deficiency of either CRT or LRP1 in mice is embryonic lethal, 
inducible or tissue-specific knockout mice may facilitate functional in vivo 
experiments. 
In any mouse experiment, it is important to consider differences in strain 
background, genetic mutations and environmental conditions. Functional and 
genetic differences have been reported in C57BU6 mice ordered from different 
vendors 137. In addition, the local housing environment and chow diet affect the 
mouse gut microbiome 138. All mice used in this study were bred in a C57BU6 
background. For AdipoR1-KO and AdipoR2-KO experiments, littermate wild-type 
controls were used. For studies involving in-house bred APN-KO, Tcad-KO or 
TA-dKO mice, wild type controls were ordered from Charles River labs. As a 
control, wild-type mice derived from the Tcad-KO strain were bred in-house for 
comparison. No differences in hind limb revascularization were observed 
between wild-type mice ordered from Charles River and in-house bred wild-type 
mice. 
Future directions 
A functional adiponectin-receptor interaction was identified for both T-
cadherin and AdipoR2 in a mouse model of peripheral artery disease. In a model 
of diet-induced obesity we found that all three candidate receptors (AdipoR1, 
AdipoR2, and T-cadherin) have important yet distinct roles. While, these results 
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provide important mouse genetic evidence towards understanding the in vivo role 
of adiponectin-receptor function, additional experiments should be completed. 
First, using mice deficient in only one receptor allowed us to evaluate the 
individual role of each receptor in disease processes. One limitation of this 
approach is the inability to assess a combined functional role of the adiponectin 
receptors, such as that of an AdipoR1-AdipoR2 heteromer129. Direct binding and 
functional interactions between T-cadherin and AdipoR1 or AdipoR2 should also 
be evaluated. Since T-cadherin lacks transmembrane and intracellular domains 
it requires interaction with a transmembrane protein for intracellular signaling. 
We identified novel roles for both T-cadherin and AdipoR2 in mediating the 
revascularization actions of adiponectin and adiponectin may signal through aT-
cadherin-AdipoR2 receptor complex. T-cadherin binds and localizes adiponectin 
to myocytes and endothelial cells and AdipoR2 allows for intracellular signaling. 
Adiponectin promotes revascularization responses in endothelial cells via AMPK, 
Akt and COX-2 signaling pathways47•52•53. While numerous studies have 
evaluated adiponectin-mediated signaling, the pathways specific to the 
interactions of adiponectin with T -cadherin and AdipoR2 should be tested. In the 
clinic, tissue expression of AdipoR2 and T -cadherin should be evaluated in 
samples isolated from subjects with peripheral artery disease. Elevation of 
serum adiponectin levels and tissue expression ofT -cadherin and AdipoR2 in 
peripheral artery disease may improve blood flow and promote limb function in 
affected patients. 
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AdipoR1-KO mice did not display an impaired revascularization response 
in the model of hind limb ischemia. However, we cannot exclude its contribution 
to revascularization. A previous study found that in vitro siRNA knockdown of 
AdipoR1 prevented adiponectin-induced phosphorylation of AMPK in endothelial 
cells53. We found that endothelial cells with reduced expression of either 
AdipoR 1 or AdipoR2 did not display adiponectin-stimulated proliferation or 
migration compared to control cells (data not shown). Future experiments should 
be completed to determine if mice deficient in AdipoR1 show improved 
revascularization to exogenous adiponectin as was observed in wild-type mice. 
In the setting of cutaneous wound healing, adiponectin enhances keratinocyte 
proliferation leading to a more rapid recovery. AdipoR1-KO mice did not display 
a baseline deficit in skin closure; however, when treated with adiponectin, wound 
healing was not accelerated as in wild-type mice117• Recent studies claim that 
the actions of adiponectin may be mediated through at least two additional 
receptors: progestin and adipoQ receptor 3 (PAQR3 renamed AdipoR3)139•140 
and AdipoRX141 . PAQR1 and PAQR2 are alternate names for AdipoR1 and 
AdipoR2140 and it is possible that other members of this poorly characterized 
PAQR family may confer actions of adiponectin or related CTRP proteins. 
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Summary 
Adiponectin receptors T-cadherin, AdipoR1 and AdipoR2 have important 
and divergent roles in adiponectin tissue localization, revascularization and 
metabolic function . Key findings of this thesis include the following: 
• Expression ofT -cadherin is required for localization of adiponectin to 
skeletal muscle tissue. 
• Hydrodynamic delivery of adiponectin plasmid promotes blood flow 
recovery in a mouse model of hind limb ischemia by elevating circulating 
levels of adiponectin. 
• T -cadherin and AdipoR2 are essential for adiponectin-mediated 
revascularization. 
• In a mouse model of metabolic dysfunction, AdipoR1-deficiency is 
deleterious whereas AdipoR2-deficiency is protective. 
An improved understanding of the relationship between adiponectin and 
its receptors may provide novel targets for the development of metabolic and 
vascular-based therapeutics. 
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FIGURE A-1 . Baseline metabolic characteristion of APN-KO and Tcad-KO mice. A) 
Glucose tolerance tests were pe1formed on wild type and APN-KO mice fed a normal chow 
diet (8-1 0 weeks-old). Mice were fasted overnight before intraperitoneal injection of 1.0g 
glucose/kg body weight. Blood glucose levels were monitored at the following time points by 
theAccu-ChekAvivaglucose monitoring system: 0. 15. 30, 60. 90 and 120 minutes. B) 
Glucose tolerance tests were pe1formed on 8-10 week-old wild type and Tcad-KO mice as 
described above. C) Body weights of age-matched male \NT, APN-KO and Tcad-KO mice. 
69 
12W CHOW DIET 12WHF/HSDIET 
A B 
i -;; E 
* 
"' "' '-
,940 
.3! 
~ * :E 
"' ~ 20 ~ 20 >-
.fi' ., 
0 0 
m m 
0 
c D 
w 
u 500 500 z 
-+- WT ...... WT c( ~ :::;- * n: l400 -•· TCADKO ""400 ,!~~ * -• · TCAD KO w 
* l ...I ,r---l---~i_ --- --~- * ~ <U300 .. 300 --,i---~i w ~ ~ , , 
" ~--~ " , (/) a200 a200 ' 0 / -~
' ' u ., w ., • ::t g100 g 100 
...I m m ~ 
0 15 30 60 90 120 0 15 30 60 90 120 
Time (ninutes) Time (ninutes) 
FIGURE A-2. Metabolic characterization Tcad-KO mice fed a chow or high fat/high 
sucrose diet. A) Body weights of wild-type and Tcad-KO mice fed a chow or B) high fat/high 
sucrose diet for 12 weeks. C) Glucose tolerance test results after 12 weeks of chow or D) 
high fat/high sucrose diet. Mean± SEM, n = 4-13, *p < 0.05 
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FIGURE A-3. Baseline metabolic characterization of AdipoR1-KO and AdipoR2-KO 
mice. A) Body weight of 9-11 week-old wild-type and AdipoR1-KO mice fed a normal chow 
diet. Mean± SEM. n = 8-12. *p < 0.05. B,C) Glucosetolerancetestand insulintolerance 
test results. Mean ± SEM. n = 3-5. D) Body weight of 9-11 week-old wild-type and AdipoR2-
KO mice fed a normal chow diet. Mean ± SEM. n = 9-12. *p < 0.05. E. F) Glucose tolerance 
test and insulin tolerance test results. Mean ± SEM. n = 4-6. 
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FIGURE A-4. Metabolic characterization AdipoR1-KO mice fed a high fat/high sucrose 
diet. A) Body weights of wild-type and AdipoR1-KO mice fed a high fat/high sucrose diet for 
4 weeks or B) 8 weeks. C) Glucose tolerance test results after 4 weeks and D) 8 weeks of 
diet. E) Insulin tolerance test performance after 4 weeks and F) 8 weeks of diet. 
Mean ± SEM, n = 8-12, *p < 0.05 
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FIGURE A-5. Metabolic characterization AdipoR2-KO mice fed a high fatlhigh sucrose 
diet. A) Body weights of wild-type and AdipoR2-KO mice fed a high fat/high sucrose diet for 
4 weeks or B) 8 weeks. C) Glucose tolerance test results after 4 weeks and D) 8 weeks of 
diet. E) Insulin tolerance test performance after 4 weeks and F) 8 weeks of diet. 
Mean± SEM, n = 9-11, *p < 0.05 
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